Literature DB >> 26802902

Probing the role of λ6 immunoglobulin light chain dimerization in amyloid formation.

Mathieu Laporte Wolwertz1, Phuong Trang Nguyen1, Noé Quittot1, Steve Bourgault2.   

Abstract

Light chain amyloidosis (AL) is a lethal disease associated with the deposition of misfolded immunoglobulin light chains (LC) as amyloid fibrils in the extracellular space of vital organs. The exact mechanisms of LC self-assembly and the molecular basis leading to cellular and organ failure still remain poorly understood. In this study, we investigated the relationship between the quaternary structure, the stability and the amyloidogenecity of LC variable domain (VL) from the λ6 germline. We observed that the amyloidogenic λ6 Wil and its non-amyloidogenic counterpart Jto dimerize in a concentration-dependent manner and that the dimer affinity is considerably decreased in the presence of a high ionic strength. Our results showed that the dimeric state delays the structural conversion associated with amyloid formation and that the monomer is critical to initiate amyloidogenesis. Thermal and chemical unfolding studies revealed that the dimeric state of VL λ6 has an equivalent stability to the monomer. This indicates that the protective effect of dimerization is not related to thermodynamic stability but, most likely, resides in specific structural features. The toxicity of monomeric Jto and Wil as well as fibrillar aggregates was evaluated on cardiomyoblasts and ThT-negative proteospecies reduced cellular viability when employed at high concentration. This study provides novel insights into the complex process of LC amyloidogenesis and suggests that dimer stabilization constitutes a promising strategy to prevent self-assembly and amyloid deposition.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aggregation; Amyloid; Dimerization; Immunoglobulin; Lambda germline; Light chain amyloidosis

Mesh:

Substances:

Year:  2016        PMID: 26802902     DOI: 10.1016/j.bbapap.2016.01.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Authors:  Gareth J Morgan; Nicholas L Yan; David E Mortenson; Enrico Rennella; Joshua M Blundon; Ryan M Gwin; Chung-Yon Lin; Robyn L Stanfield; Steven J Brown; Hugh Rosen; Timothy P Spicer; Virneliz Fernandez-Vega; Giampaolo Merlini; Lewis E Kay; Ian A Wilson; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

2.  Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?

Authors:  Gareth J Morgan; Grace A Usher; Jeffery W Kelly
Journal:  Biochemistry       Date:  2017-12-04       Impact factor: 3.162

3.  The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.

Authors:  Gareth J Morgan; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2016-08-26       Impact factor: 5.469

4.  Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.

Authors:  Manuel Hora; Martin Carballo-Pacheco; Benedikt Weber; Vanessa K Morris; Antje Wittkopf; Johannes Buchner; Birgit Strodel; Bernd Reif
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

5.  Identification of transmissible proteotoxic oligomer-like fibrils that expand conformational diversity of amyloid assemblies.

Authors:  Phuong Trang Nguyen; Ximena Zottig; Mathew Sebastiao; Alexandre A Arnold; Isabelle Marcotte; Steve Bourgault
Journal:  Commun Biol       Date:  2021-08-05

6.  Biochemical and biophysical characterisation of immunoglobulin free light chains derived from an initially unbiased population of patients with light chain disease.

Authors:  Rebecca Sternke-Hoffmann; Amelie Boquoi; David Lopez Y Niedenhoff; Florian Platten; Roland Fenk; Rainer Haas; Alexander K Buell
Journal:  PeerJ       Date:  2020-03-17       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.